AbbVie

YTD

ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.

CEO

Robert A. Michael

CEORobert A. Michael

Employees

55,000

Employees55,000

Headquarters

North Chicago, Illinois

HeadquartersNorth Chicago, Illinois

Founded

2011

Founded2011

Employees

55,000

Employees55,000

ABBV Key Statistics

Market cap

336.99B

Market cap336.99B

Price-Earnings ratio

81.01

Price-Earnings ratio81.01

Dividend yield

3.36%

Dividend yield3.36%

Average volume

8.15M

Average volume8.15M

High today

$192.59

High today$192.59

Low today

$189.53

Low today$189.53

Open price

$190.30

Open price$190.30

Volume

4.66M

Volume4.66M

52 Week high

$218.66

52 Week high$218.66

52 Week low

$163.52

52 Week low$163.52

ABBV News

TipRanks 2d

AbbVie’s New Migraine Study: A Potential Game-Changer for Adolescents

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...

TipRanks 2d

AbbVie Stock Jumps on $2.1B Capstan Therapeutics Deal

AbbVie (ABBV) stock rallied on Monday after the company announced its $2.1 billion agreement to acquire Capstan Therapeutics. It will use cash to fund this tran...

Seeking Alpha 3d

AbbVie to acquire Capstan Therapeutics for up to $2.1B in cash

AbbVie (NYSE:ABBV) has agreed to acquire clinical-stage biotechnology company Capstan Therapeutics for up to $2.1 billion in cash. The transaction is subject t...

Analyst ratings

60%

of 30 ratings

Buy

60%

Hold

40%

Sell

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.